Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care

NCT ID: NCT00950534

Last Updated: 2011-11-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-07-31
• Study Completion Date: 2010-08-31

Brief Summary

The primary objective is to demonstrate the improvement in glycosylated haemoglobin (HbA1c) levels after general practitioner (GP) initiation and management of type 2 diabetes mellitus (T2DM) with insulin glargine compared with their usual clinical practice.

The secondary objective is to demonstrate the importance of GP initiation of insulin glargine for the treatment of T2DM.

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

General Practitioner initiation with insulin glargine

Patients will be prescribed insulin glargine by their Investigator and they will be taught how to administer insulin glargine according to Australian guidelines. Patients will be treated for 24 weeks.

Group Type: EXPERIMENTAL

INSULIN GLARGINE (HOE901)

Intervention Type: DRUG

The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)

Usual standard of care

Patients will be treated by their Investigator with the usual standard of care for 24 weeks (e.g., OAD dose titration, addition of a second or third OAD, or referral to an endocrinologist)

Group Type: ACTIVE_COMPARATOR

Oral Anti Diabetics (OAD)

Intervention Type: DRUG

Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L

Interventions

INSULIN GLARGINE (HOE901)

The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)

Intervention Type: DRUG

Oral Anti Diabetics (OAD)

Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosed with type 2 Diabetes Mellitus (T2DM)
• HbA1c > or = 7.5%, or HbA1c < or = 10%
• Continuous oral antidiabetic (OAD) treatment for more or equal than three months before randomisation with stable daily doses of one or more OADs (if on two or more OADs, one must be less or equal than half maximum tolerated dose)
• Willing and able to perform blood glucose monitoring using a blood glucose meter
• Willing and able to keep a daily patient diary
• Willing and able to provide written informed consent before enrolment in the study

Exclusion Criteria

• Type 1 diabetes mellitus
• Body mass index (BMI) > 45 kg/m²
• Works night shifts
• History of ketoacidosis or hyperosmolar hyperglycaemic state
• History of stroke, myocardial infarction, angina pectoris, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the previous 12 months
• History of congestive heart failure
• Hypoglycaemia unawareness
• Have had more than one episode of hypoglycaemia (per protocol definition) within 24 weeks before screening
• Impaired renal function defined as, but not limited to, serum creatinine > or = 1.5 mg/dL (133 µmol/L) males or > or = 1.4 mg/dL (124 µmol/L) females
• Active liver disease (alanine transaminase (ALT) greater than two times the upper limit of the reference range, as defined by the local laboratory)
• Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol
• Had a blood transfusion or severe blood loss within the 3 months before screening, or have known haemoglobinopathy, haemolytic anaemia or sickle cell anaemia
• Current or previous use of insulin
• Known hypersensitivity / intolerance to insulin glargine or any of its excipients
• Have taken exenatide in the six weeks before screening or for a total of 30 days or more in the 24 weeks before screening
• Currently receiving treatment with non-selective -blockers
• Currently receiving chronic (longer than two weeks) systemic glucocorticoid therapy (excluding topical or inhaled preparations) or have received such therapy within the four weeks preceding the screening visit
• Currently undergoing therapy or planned radiological examinations requiring the administration of contrasting agents for malignancy (other than non-metastatic / early stage basal cell or squamous cell carcinoma).
• Currently participating in another investigational study or recent study participation ending < 30 days before screening
• Female patients who are pregnant or breastfeeding
• Female patients of childbearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be willing to agree to use a medically accepted contraceptive regimen for the duration of the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Sanofi-Aventis Administrative Office

Macquarie Park, , Australia

Countries

Australia

Other Identifiers

LANTU_L_04264

Identifier Type: -

Identifier Source: org_study_id